The Tumor Immunology Laboratory studies the immunological landscape of cancer with a specific emphasis on tumor-specific T and B cell responses in human papillomavirus-positive (HPV+) head and neck cancer (HNC). Recent studies demonstrated that the presence of B cell in the tumor microenvironment, especially in the form of tertiary lymphoid structures, is associated with improved response rates to immune checkpoint inhibition (ICI). However, how B cells contribute to improved ICI responses is not known. 

Our data show that HPV-specific B cells and CD8+ T cells are readily detectable in HPV+ HNC tumors, with active secretion of HPV-specific antibodies in situ (Wieland et al., Nature 2021; Eberhardt et al., Nature 2021). Thus, a major focus of our lab is to gain a better understanding of the role of these intratumoral B cells in anti-tumor immunity. 

These data will aid in the development of novel immunotherapeutic strategies harnessing the therapeutic potential of tumor-specific B cells and synergizing with current immunotherapies to ultimately improve patient outcomes.

Our objectives

The objectives of our lab include identifying the major antigenic determinants of intratumoral B and T cells in HPV+ HNC, explaining the mechanisms by which intratumoral B cells impact anti-tumor T cell responses, and developing novel HPV-specific human monoclonal antibodies from intratumoral B cells.

Our team

Wieland Andreas 460x460

Andreas Wieland, PhD

Lab director

  • Arline Joachim, BS
Our publications

Our publications

Contact us

We are always looking for highly motivated people to join our group and work on various projects in the realm of immuno-oncology. If interested, please reach out to

Graduate students interested in lab rotations and undergraduates looking for research experience, please email Dr. Wieland.

Prospective postdoctoral fellows interested in immune-oncology, please email Dr. Wieland with a cover letter stating your research interests, your latest CV and contact information of three references.

Follow us on Twitter

View Twitter